History and progress of hypotheses and clinical trials for Alzheimer’s disease  

作　　者：Pei-Pei Liu Yi Xie Xiao-Yan Meng Jian-Sheng Kang 

机构地区：[1]Clinical Systems Biology Laboratories,The First Affiliated Hospital of Zhengzhou University,Zhengzhou,450052 Henan,China

出　　处：《Signal Transduction and Targeted Therapy》2019年第1期412-433,共22页信号转导与靶向治疗（英文）

基　　金：We appreciate funding by the National Natural Science Foundation of China(Grant No.31171369);the National Basic Research Program(973 Program)(Nos 2011CB910903 and 2010CB912001);the Chinese Academy of Sciences(Hundred Talents Program and 2009OHTP10);the Joint Construction Project of Henan Province(No.2018020088 and No.2018020114),and the First Affiliated Hospital of Zhengzhou University.

摘　　要：Alzheimer’s disease(AD)is a neurodegenerative disease characterized by progressive memory loss along with neuropsychiatric symptoms and a decline in activities of daily life.Its main pathological features are cerebral atrophy,amyloid plaques,and neurofibrillary tangles in the brains of patients.There are various descriptive hypotheses regarding the causes of AD,including the cholinergic hypothesis,amyloid hypothesis,tau propagation hypothesis,mitochondrial cascade hypothesis,calcium homeostasis hypothesis,neurovascular hypothesis,inflammatory hypothesis,metal ion hypothesis,and lymphatic system hypothesis.However,the ultimate etiology of AD remains obscure.In this review,we discuss the main hypotheses of AD and related clinical trials.Wealthy puzzles and lessons have made it possible to develop explanatory theories and identify potential strategies for therapeutic interventions for AD.The combination of hypometabolism and autophagy deficiency is likely to be a causative factor for AD.We further propose that fluoxetine,a selective serotonin reuptake inhibitor,has the potential to treat AD.

关 键 词：ALZHEIMER METABOLISM CLINICAL 

分 类 号：R74[医药卫生—神经病学与精神病学]